Kiniksa Pharmaceuticals, Ltd. (KNSA) AI Stock Analysis

Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company dedicated to identifying, acquiring, developing, and commercializing therapeutic medications tailored for patients globally with severe and unmet medical needs. Its commercial and pipeline portfolio includes ARCALYST, an interleukin-1alpha and interleukin-1beta inhibitor for recurrent pericarditis. The company has also advanced Mavrilimumab through Phase II trials for giant cell arteritis, while Vixarelimab is in Phase 2a clinical trials for prurigo nodularis. Additionally, Kiniksa is developing KPL-404, a monoclonal antibody designed to inhibit the CD40-CD154 interaction involved in B-cell maturation and immune responses. Established in 2015, the company is headquartered in Hamilton, Bermuda.

Kiniksa has expanded annual revenue from $38.5M in FY2021 to $677.6M in FY2025, representing a 5-year revenue CAGR of 144.8% from FY2020 to FY2025. In FY2025, revenue grew 60.1%, with an operating margin of 11.4% and net income of $59.0M, or $0.74 per share, compared to a net loss of -$43.2M in FY2024. Over the trailing twelve months ending June 30, 2026, revenue totaled $840.8M with an operating margin of 11.2%. In the latest quarter ended June 30, 2026, quarterly revenue grew 55.4% year-over-year, while quarterly earnings increased 30.4%.

As of June 30, 2026, Kiniksa held $525.9M in cash and short-term investments against $8.9M in total debt, resulting in net cash of $517.0M. The company reported a current ratio of 3.90 and a debt-to-equity ratio of 0.01 on shareholders' equity of $654.1M. In FY2025, operating cash flow and free cash flow were both $25.4M, with capital expenditures of $277,000. Capital allocation in FY2025 included $7.7M spent on share buybacks, while the share count increased 20.9% over five years.

At a last close of $78.59, Kiniksa trades at a trailing P/E of 79.4x and a forward P/E of 59.5x, above the median of its US-listed Healthcare peers of 24.6x trailing and 17.3x forward. Its enterprise value of $5.41B implies an EV/EBITDA multiple of 53.1x versus the peer median of 12.0x, and its price-to-sales multiple is 7.3x compared to 4.1x for peers. Over the past year, the stock returned 101.9%, outperforming the S&P 500 (SPY) return of 16.8%, and is up 586.4% over five years compared to 83.0% for the index.

Kiniksa carries 7 Strong Buy ratings, 1 Buy rating, and no Hold or Sell ratings among covering analysts. The mean price target is $98.00, representing a 24.7% premium over the last close of $78.59. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $994.4M and EPS of $1.16, implying 54.3% EPS growth. For FY2027, four analysts project revenue of $1.22B and EPS of $1.62. Kiniksa beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is October 27, 2026.

This page is an AI-written research summary of Kiniksa Pharmaceuticals, Ltd. (KNSA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: KNSA income statement, KNSA balance sheet, KNSA key metrics, KNSA analyst forecast, KNSA chart. See the KNSA stock overview for the latest quote and news.